Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Change in Receivables (2016 - 2025)

Ocular Therapeutix (OCUL) has 13 years of Change in Receivables data on record, last reported at -$118000.0 in Q4 2025.

  • For Q4 2025, Change in Receivables fell 105.48% year-over-year to -$118000.0; the TTM value through Dec 2025 reached -$1.7 million, down 127.99%, while the annual FY2025 figure was -$1.7 million, 127.99% down from the prior year.
  • Change in Receivables reached -$118000.0 in Q4 2025 per OCUL's latest filing, down from $356000.0 in the prior quarter.
  • Across five years, Change in Receivables topped out at $6.2 million in Q2 2023 and bottomed at -$7.2 million in Q1 2025.
  • Average Change in Receivables over 5 years is $919900.0, with a median of $1.1 million recorded in 2021.
  • The widest YoY moves for Change in Receivables: up 11766.67% in 2025, down 2052.86% in 2025.
  • A 5-year view of Change in Receivables shows it stood at $1.6 million in 2021, then fell by 3.79% to $1.5 million in 2022, then skyrocketed by 70.06% to $2.6 million in 2023, then fell by 16.87% to $2.2 million in 2024, then plummeted by 105.48% to -$118000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Receivables were -$118000.0 in Q4 2025, $356000.0 in Q3 2025, and $5.2 million in Q2 2025.